-transparent.png){kind=logo}
Cardiotoxicity of doxorubicin, 2 mg/kg i.p. twice weekly in rats, was assessed by serial electrocardiography and electron microscopy. The toxic effects were markedly inhibited by ICRF-159, 50 mg/kg p.o. given 1 h before doxorubicin. The development of nephropathy characterized by proteinuria, hyperlipidemia and glomerular and tubular changes was significantly retarded, and the degenerative changes of peripheral nerves were markedly reduced. On the other hand, ICRF-159 enhanced the depressant effects of doxorubicin on bone marrow function. Doxorubicin reduced body weight gain, caused ascites, decrease in heart and thymus weight, and increase in liver and kidney weight. These changes were also inhibited or attenuated by ICRF-159 pretreatment.
S Tian Hu, and
E Brändle, and
G Zbinden
April 1984,
Tumori,
S Tian Hu, and
E Brändle, and
G Zbinden
August 1984,
The British journal of surgery,
S Tian Hu, and
E Brändle, and
G Zbinden
July 1973,
British journal of cancer,
S Tian Hu, and
E Brändle, and
G Zbinden
January 1981,
Cancer treatment reports,
S Tian Hu, and
E Brändle, and
G Zbinden
May 1973,
Biomedicine / [publiee pour l'A.A.I.C.I.G.],
S Tian Hu, and
E Brändle, and
G Zbinden
January 1987,
Cancer chemotherapy and pharmacology,
S Tian Hu, and
E Brändle, and
G Zbinden
September 2009,
Journal of medical toxicology : official journal of the American College of Medical Toxicology,
